A study identifying which biomarkers are predictive of a good clinical response following treatment with Xolair in patients with severe asthma

Trial Profile

A study identifying which biomarkers are predictive of a good clinical response following treatment with Xolair in patients with severe asthma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Asthma
  • Focus Biomarker; Pharmacodynamics
  • Acronyms SoMOSA
  • Sponsors Novartis
  • Most Recent Events

    • 11 Apr 2017 Status changed from active, no longer recruiting to recruiting.
    • 03 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top